Biohaven Unveils Promising BHV-1530 Cancer Data at ESMO
NEW HAVEN, Conn., July 20, 2026 Biohaven Ltd. has announced that new Phase I clinical data for BHV-1530, its...
licensing deal
Advertisement
Halozyme and Incyte Join Forces to Improve Cancer Drug Delivery
SAN DIEGO, July 20, 2026 Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to...
SNIS 2026 Unveils AI Breakthrough in Brain Tumor Treatment
SEATTLE, July 20, 2026 The Society of NeuroInterventional Surgery (SNIS) has unveiled a series of groundbreaking scientific presentations for...
Mission Sells MTX652 to Dimerix in $292M Deal
Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...
Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
Advertisements
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
HanchorBio Expands Global Growth Strategy With Taiwan Listing and HCB101 Clinical Progress
TAIPEI, Taiwan, SHANGHAI, China and SAN FRANCISCO, California — May 28, 2026 HanchorBio, Inc. announced that the company will...
Arrowhead Pharmaceuticals and Madrigal Announce MASH Deal
PASADENA, Calif., United States – May 5, 2026 Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement...
Cue Biopharma Expands Anti-IgE Pipeline in $691M Deal
Boston, USA | April 30, 2026 Cue Biopharma has entered into a strategic licensing agreement with Ascendant Health Sciences...
Dogwood Therapeutics Secures $100M Partnership for Antiviral Assets
Alpharetta, Georgia, USA – April 23, 2026 Dogwood Therapeutics announced a global development and commercialization partnership with PRIDCor Therapeutics...
Advertisement
